AIR: No Impact of Switching From 3-Drug to 2-Drug ART on Adverse Disease Outcomes in Virologically-Suppressed Persons With HIV

July 6-10, 2020; Virtual
Switching to 2-drug ART did not increase risk of virologic suppression, serious non-AIDS events, or death in virologically suppressed persons with HIV.
Format: Microsoft PowerPoint (.ppt)
File Size: 219 KB
Released: July 10, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Produced in collaboration with
Educational grant provided by:
Gilead Sciences
ViiV Healthcare
Merck Sharp & Dohme Corp.

Related Content

Download expert-authored CCO slides reviewing data and guidelines on management of heavily-treatment experienced patients with HIV

Joseph J. Eron, Jr., MD
Program Director
Princy N. Kumar, MD, FIDSA, MACP
Program Director
Eric S. Daar, MD
Released: March 2, 2021

Download CCO slides reviewing data and guidelines on management of heavily-treatment experienced patients with HIV experiencing treatment failure

Princy N. Kumar, MD, FIDSA, MACP Brian Wood, MD Released: February 22, 2021

Expert commentary on managing a TB outbreak in a socially and medically complex population of patients living with HIV

Nicky Mehtani, MD, MPH Released: February 22, 2021

Multimedia module from Clinical Care Options: HIV experts review new/emerging strategies for initial HIV treatment, switching ART, and HIV prevention

Joseph J. Eron, Jr., MD
Program Director
Princy N. Kumar, MD, FIDSA, MACP
Program Director
Daniel R. Kuritzkes, MD Paul E. Sax, MD
Physicians: maximum of 1.25 AMA PRA Category 1 Credits Registered Nurses: 1.25 Nursing contact hours Pharmacists: 1.25 contact hours (0.125 CEUs) Released: December 30, 2020 Expired: December 29, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue